相关实验视频

Updated: Jul 17, 2025

MEDUSA for Identifying Death Regulatory Genes in Chemo-genetic Profiling Data

MEDUSA for Identifying Death Regulatory Genes in Chemo-genetic Profiling Data

Published on: February 7, 2025

在HL60细胞中以太胺抗性的分子决定因素

Rasha H Alghamdi^1,2,3, Farid Ahmed^1,4, Sara M Ibrahim²

¹Center of Excellence in Genomic Medicine Research, King Abdulaziz University, P.O. Box 80216, Jeddah21589, Kingdom of Saudi Arabia.

|September 1, 2023

概括

急性髓性白血病 (AML) 中的化疗耐药性阻碍了治疗的成功. 这项研究确定了SRC氨酸激酶家族基因的上调作为ETOPOSIDE耐药AML细胞中的关键机制.

科学领域:

血液学血液学血液学
分子生物学分子生物学
癌症研究癌症研究

背景情况:

化疗耐药性是急性髓性白血病 (AML) 治疗失败和死亡的主要原因.
埃托波西德是一种DNA拓酶II抑制剂,是治疗复发性/耐药性AML的关键药物,通常用于组合疗法.
了解埃托胺耐药性的机制对于改善AML治疗结果至关重要.

研究的目的:

调查和阐明在急性髓性白血病 (AML) 中的埃托化物耐药性背后的分子机制.
为了确定与AML细胞系中获得的对etoposide的耐药性相关的特定遗传变化或途径.

主要方法:

通过渐进的药物暴露,产生抗以托波的HL60细胞系 (HL60-EtopR H1A,HL60-EtopR H1B,HL60-EtopR H1C).
与父细胞相比,具有显著增加的埃托化物耐药性的耐药克隆的隔离和特征.
基于微阵列的基因表达造型,以比较耐药和亲细胞系之间的分子差异.

主要成果:

已经确立的抗埃托化物HL60克隆具有2.39至4.78倍的抗性.
基因表达特征分析显示,在耐埃托化体细胞中,SRC氨酸激酶家族基因的显著上调.
确定了潜在的分子标,涉及到AML中埃托胺耐药性的发展.

结论:

基因上调的Src氨酸激酶家族的基因与AML中埃托化物耐药性的机制有关.
向Src氨酸激酶可能代表一种潜在的治疗策略,以克服AML患者的etoposide耐药性.
需要进一步的研究,以验证Src抑制剂在克服AML中的埃托胺耐药性的作用.

关键词:

在急性髓性白血病中.细胞灭亡 (apoptosis) 是一种死亡的过程.癌症癌症癌症癌症化疗化疗是一种化学疗法.这种类型的Etoposide.多种药物耐药性多种药物耐药性

更多相关视频

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...